{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:50Z","timestamp":1791912470683,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.nmd.2026.106386","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:20:58Z","timestamp":1771978858000},"page":"106386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Zilucoplan is effective for ravulizumab-refractory generalized myasthenia gravis with the C5 p.Arg885His variant: a case report"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8413-5334","authenticated-orcid":false,"given":"Yuya","family":"Itagaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasumi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Akanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2026.106386_bib0001","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2026.106386_bib0002","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2026.106386_bib0003","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2026.106386_bib0004","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2026.106386_bib0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14712598.2020.1725468","article-title":"Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"20","author":"Lee","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.nmd.2026.106386_bib0006","article-title":"Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation","volume":"14","author":"Tang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2026.106386_bib0007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/cen3.12766","article-title":"Efficacy and safety of zilucoplan in Japanese patients with generalized myasthenia gravis: a subgroup analysis of the phase III randomized RAISE study","volume":"15","author":"Utsugisawa","year":"2024","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.1016\/j.nmd.2026.106386_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104134","article-title":"The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms","volume":"29","author":"Bouwman","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.nmd.2026.106386_bib0009","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood.V126.23.1209.1209","article-title":"C5 polymorphism in a dutch patient with paroxysmal nocturnal hemoglobinuria (PNH) and no Asian ancestry, resistant to eculizumab, but in vitro sensitive to coversin","volume":"126","author":"Langemeijer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.nmd.2026.106386_bib0010","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/acn3.51376","article-title":"Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses","volume":"8","author":"Howard","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2026.106386_bib0011","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","article-title":"Complement inhibitor therapy for myasthenia gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2026.106386_bib0012","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/bloodadvances.2016002832","article-title":"Use of the complement inhibitor Coversin to treat HSCT-associated TMA","volume":"1","author":"Goodship","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.nmd.2026.106386_bib0013","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/bjh.16305","article-title":"Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan)","volume":"188","author":"Schols","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nmd.2026.106386_bib0014","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.nmd.2026.106386_bib0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.nmd.2026.106386_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.696385","article-title":"Eculizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"12","author":"Monteleone","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2026.106386_bib0017","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s00415-023-11617-1","article-title":"Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"270","author":"Vu","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2026.106386_bib0018","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2026.106386_bib0019","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1182\/blood-2019-122421","article-title":"Discordance between free C5 and CH50 complement assays in measuring complement C5 inhibition in patients with aHUS treated with ravulizumab","volume":"134","author":"Cataland","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.nmd.2026.106386_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264489","article-title":"Myasthenia gravis complement activity is independent of autoantibody titer and disease severity","volume":"17","author":"Fichtner","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2026.106386_bib0021","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1007\/s00415-024-12234-2","article-title":"Ravulizumab in myasthenic crisis: the first case report","volume":"271","author":"Konen","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2026.106386_bib0022","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1007\/s10072-023-06900-y","article-title":"Starting eculizumab as rescue therapy in refractory myasthenic crisis","volume":"44","author":"Vinciguerra","year":"2023","journal-title":"Neurol Sci"},{"key":"10.1016\/j.nmd.2026.106386_bib0023","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/muscles3010005","article-title":"Eculizumab as additional rescue therapy in myasthenic crisis","volume":"3","author":"Crescenzo","year":"2024","journal-title":"Muscles"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626000544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626000544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T03:58:17Z","timestamp":1774497497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896626000544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"alternative-id":["S0960896626000544"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2026.106386","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zilucoplan is effective for ravulizumab-refractory generalized myasthenia gravis with the C5 p.Arg885His variant: a case report","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2026.106386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106386"}}